Multibagger Pharma Stock Jumps After Board Announces Record Date for 1:1 Bonus Share Multibagger Pharma Stock Jumps After Board Announces Record Date for 1:1 Bonus Share The company has a market cap of over Rs 1,000 crore and the stock has given multibagger returns of 250 per cent in just 2 years. DSIJ Intelligence-1 / Wednesday, June 25, 2025 / Article rating: 3.0 The shares of the company have a PE of 38x, an ROE of 17 per cent and an ROCE of 23 per cent.
Low PE Pharma Penny Stock Below 60 Rockets Over 10 Per Cent Today with Heavy Volume; Here’s Why! Low PE Pharma Penny Stock Below 60 Rockets Over 10 Per Cent Today with Heavy Volume; Here’s Why! The company has a market cap of over Rs 400 crore and the stock is up by 16.67 per cent from its 52-week low of Rs 49.20 per share. DSIJ Intelligence-1 / Monday, June 9, 2025 / Article rating: 5.0 The company has a market cap of over Rs 400 crore and the stock is up by 16.67 per cent from its 52-week low of Rs 49.20 per share.
Promoters hold 65.99 per cent stake: Low PE pharma penny stock below Rs 60; Company announces significant global expansion and strategic integration Promoters hold 65.99 per cent stake: Low PE pharma penny stock below Rs 60; Company announces significant global expansion and strategic integration The company has a market cap of Rs 287 crore and the stock is up by 6 per cent from its 52-week low of Rs 49.20 per share. DSIJ Intelligence-1 / Sunday, June 8, 2025 / Article rating: 3.3 The shares of the company have a PE of 12x whereas the industry PE is 36x.
From Rs 6.27 to Rs 30.38 per share: Pharma company received certificate of recognition, One Star Export House from Government of India From Rs 6.27 to Rs 30.38 per share: Pharma company received certificate of recognition, One Star Export House from Government of India The stock gave multibagger returns of 385 per cent from its 52-week low of Rs 6.27 per share. DSIJ Intelligence-1 / Thursday, June 5, 2025 / Article rating: 3.1 The stock gave multibagger returns of 385 per cent from its 52-week low of Rs 6.27 per share.
40 Per Cent Returns from 52-Week Low; Board Announce 1:1 Bonus Shares and 30 Per Cent Dividend 40 Per Cent Returns from 52-Week Low; Board Announce 1:1 Bonus Shares and 30 Per Cent Dividend The stock is up over 40 per cent from its 52-week low of Rs 148.05 per share. DSIJ Intelligence-1 / Sunday, May 25, 2025 / Article rating: 3.6 The stock is up over 40 per cent from its 52-week low of Rs 148.05 per share.
47 Per Cent Returns from 52-Week Low; Board Likely to Announce Bonus Shares and Dividend 47 Per Cent Returns from 52-Week Low; Board Likely to Announce Bonus Shares and Dividend The stock is up by 47 per cent from its 52-week low of Rs 148.05 per share. DSIJ Intelligence-1 / Tuesday, May 20, 2025 / Article rating: 4.6 The company has a market cap of over Rs 1,000 crore and has delivered good profit growth of 19 per cent CAGR over the last 5 years with a healthy dividend payout of 26 per cent.
CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share. DSIJ Intelligence-1 / Wednesday, May 14, 2025 / Article rating: 5.0 The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.
Pharma penny stock under Rs 40 bags new order worth USD 1,38,075 from Taha Drugs & Chemicals Co. Ltd Pharma penny stock under Rs 40 bags new order worth USD 1,38,075 from Taha Drugs & Chemicals Co. Ltd The stock is up 11.15 per cent from its 52-week low of Rs 35.70 per share.. DSIJ Intelligence-1 / Monday, May 5, 2025 / Article rating: 4.3 The stock is up 11.15 per cent from its 52-week low of Rs 35.70 per share.
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg. DSIJ Intelligence-1 / Monday, April 14, 2025 / Article rating: 5.0 The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.
Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share. DSIJ Intelligence-1 / Thursday, April 3, 2025 / Article rating: 4.5 The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.